港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增生物资产公允价值正向变动成为核心驱动力

智通财经08-07

【港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增生物资产公允价值正向变动成为核心驱动力】智通财经APP获悉，昭衍新药(06127.HK)涨超11%，截至发稿，涨11.42%，报27.32港元，成交额3.34亿港元。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2657361881?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-07 15:20","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2657361881","market":"hk","top_or_hot":-1,"title":"港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力】</b>智通财经APP获悉，昭衍新药(06127.HK)涨超11%，截至发稿，涨11.42%，报27.32港元，成交额3.34亿港元。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力】</b>智通财经APP获悉，昭衍新药(06127.HK)涨超11%，截至发稿，涨11.42%，报27.32港元，成交额3.34亿港元。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2657361881","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657361881","pubTimestamp":1786087248,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力】智通财经APP获悉，昭衍新药(06127.HK)涨超11%，截至发稿，涨11.4","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06127":"昭衍新药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念"},"translate_title":"Changes in Hong Kong stocks | Zhaoyan New Drug (06127.HK) rose by more than 11%. The company's performance in the first half of the year increased significantly. Positive changes in the fair value of biological assets became the core driving force","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06127":1.5},"content_text":"【港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力】智通财经APP获悉，昭衍新药(06127.HK)涨超11%，截至发稿，涨11.42%，报27.32港元，成交额3.34亿港元。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657361881","isCrawlerRequest":true}

港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力

精彩评论

港股异动 | 昭衍新药(06127.HK)涨超11% 公司上半年业绩大幅预增生物资产公允价值正向变动成为核心驱动力